Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.
Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced participation in the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 11:00 a.m. ET. Key executives, including Jennifer Good (CEO), Lisa Delfini (CFO), and David Clark (CMO), will engage in a fireside chat. They will also hold investor meetings during the conference. Trevi is developing the investigational therapy Haduvio™ (oral nalbuphine ER) for chronic cough related to idiopathic pulmonary fibrosis and prurigo nodularis. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event. Haduvio is a mixed receptor agonist and antagonist, targeting cough mediation. Safety and efficacy evaluations are pending regulatory review.
Trevi Therapeutics (TRVI) announced its fourth quarter and full-year 2022 financial results, reporting a net loss of $5.5 million for Q4, down from $8.5 million in Q4 2021. Total operating expenses decreased to $6.7 million, driven by lower R&D costs of $4.3 million. As of December 31, 2022, Trevi had $120.5 million in cash and marketable securities, which supports operations into 2026. The company plans multiple trial initiations for its investigational therapy Haduvio in chronic cough and prurigo nodularis in 2023, with FDA discussions ongoing. The full data from the Phase 2b/3 PRISM trial is expected in Q2 2023.
Trevi Therapeutics (Nasdaq: TRVI) announced a conference call scheduled for March 16, 2023, at 4:30 p.m. ET to discuss its fourth quarter and full-year financial results for 2022. The company, focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough associated with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis, encourages participation via phone or webcast. Haduvio is a mixed μ-opioid receptor antagonist and κ-opioid receptor agonist, with safety and efficacy not yet evaluated by regulatory authorities. More information can be accessed from their official website.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) announced a key milestone on March 7, 2023, as the USPTO granted a notice of allowance for the patent covering its investigational therapy Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). This patent is expected to be Orange Book-listable with an expiration in 2039, enhancing Trevi's intellectual property portfolio. Currently, there are no approved treatments for chronic cough in IPF, affecting approximately 140,000 patients in the U.S. Haduvio is a mixed opioid receptor therapy that aims to address this significant health issue.
Trevi Therapeutics (NASDAQ: TRVI) announced its participation in several upcoming conferences in March 2023. The events include the Frazier/Fenwick Winter Investor Event from March 7-10, the Oppenheimer 33rd Annual Healthcare Conference on March 13-15 with a corporate presentation on March 13 at 4:00 p.m. ET, and BIO-Europe Spring on March 20-22 (in-person) and March 28-30 (virtual). Trevi is focused on Haduvio™ (oral nalbuphine ER) for chronic cough treatment in adults with idiopathic pulmonary fibrosis and prurigo nodularis, reporting positive results from its Phase 2 CANAL trial.
Trevi Therapeutics (Nasdaq: TRVI) will present at the Emerging Growth Conference on February 22, 2023, at 10:50 a.m. ET. The presentation will focus on its investigational therapy Haduvio™ (oral nalbuphine ER) targeting chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis. Senior leadership, including Jennifer Good, David Clark, and Farrell Simon, will engage in a Q&A session following the presentation. Interested parties can register for the event and access the live webcast on Trevi’s website, with an archived replay available post-event.
Trevi Therapeutics plans to present its investigational therapy Haduvio™ at two major investor conferences in February 2023. The BIO CEO & Investor Conference will take place from February 6-9, with Trevi’s presentation scheduled for February 7 at 10:45 a.m. ET. The SVB Securities Global Biopharma Conference follows from February 13-16, where a presentation is set for February 14 at 11:20 a.m. ET. Trevi Therapeutics, trading under the symbol TRVI, is developing Haduvio for chronic cough and prurigo nodularis, having reported promising Phase 2 trial results for chronic cough in patients with idiopathic pulmonary fibrosis.
Trevi Therapeutics (Nasdaq: TRVI) announced significant business updates on Jan. 5, 2023, highlighting the progression of its investigational therapy, Haduvio™. Aiming to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis, Trevi is preparing for several clinical studies in 2023, including a Phase 2 dose-ranging study and a Phase 1b respiratory physiology study. The company is also conducting a human abuse liability study and will request an End-of-Phase 2 meeting with the FDA. Trevi will participate in key conferences starting January 9, 2023.
Trevi Therapeutics (Nasdaq: TRVI) will present at the Biotech Showcase 2023 on January 10, 2023, at 3:00 p.m. PT. This event coincides with the 12th Annual LifeSci Partners Corporate Access Event, held from January 9-11, 2023, in San Francisco, CA. Trevi is focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough and prurigo nodularis. Positive results from the Phase 2 CANAL trial for chronic cough related to idiopathic pulmonary fibrosis have prompted Trevi to prioritize further clinical development in this area.
Trevi Therapeutics has appointed David Clark, MD, MRCP, as the new Chief Medical Officer to advance the development of Haduvio™, an oral investigational therapy for chronic cough related to idiopathic pulmonary fibrosis. Dr. Clark brings over 25 years of experience in clinical development and has previously led clinical teams at several biopharmaceutical companies. He will play a critical role in executing Trevi's clinical strategies, supported by the insights from prior CMO Thomas Sciascia, who transitions to Chief Science Officer.